SG11201906422VA - Apoc-ii mimetic peptides - Google Patents
Apoc-ii mimetic peptidesInfo
- Publication number
- SG11201906422VA SG11201906422VA SG11201906422VA SG11201906422VA SG11201906422VA SG 11201906422V A SG11201906422V A SG 11201906422VA SG 11201906422V A SG11201906422V A SG 11201906422VA SG 11201906422V A SG11201906422V A SG 11201906422VA SG 11201906422V A SG11201906422V A SG 11201906422VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- delta
- gatehouse
- rockville
- suite
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 239000003814 drug Substances 0.000 abstract 4
- 108010024284 Apolipoprotein C-II Proteins 0.000 abstract 3
- 102100039998 Apolipoprotein C-II Human genes 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 abstract 1
- 241001590701 Vidia Species 0.000 abstract 1
- 208000006575 hypertriglyceridemia Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 229910052710 silicon Inorganic materials 0.000 abstract 1
- 239000010703 silicon Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1722—Plasma globulins, lactoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Marine Sciences & Fisheries (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762448358P | 2017-01-19 | 2017-01-19 | |
US201762476531P | 2017-03-24 | 2017-03-24 | |
US201762476535P | 2017-03-24 | 2017-03-24 | |
PCT/US2018/014532 WO2018136803A1 (fr) | 2017-01-19 | 2018-01-19 | Peptides mimétiques d'apoc-ii |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201906422VA true SG11201906422VA (en) | 2019-08-27 |
Family
ID=62908746
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201906422VA SG11201906422VA (en) | 2017-01-19 | 2018-01-19 | Apoc-ii mimetic peptides |
SG10201911974UA SG10201911974UA (en) | 2017-01-19 | 2018-01-19 | Apoc-ii mimetic peptides |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201911974UA SG10201911974UA (en) | 2017-01-19 | 2018-01-19 | Apoc-ii mimetic peptides |
Country Status (14)
Country | Link |
---|---|
US (2) | US11136372B2 (fr) |
EP (1) | EP3571216A4 (fr) |
JP (2) | JP7353973B2 (fr) |
KR (1) | KR20190121305A (fr) |
CN (1) | CN110831957B (fr) |
AU (1) | AU2018210404B2 (fr) |
BR (1) | BR112019014707A2 (fr) |
CA (1) | CA3050106A1 (fr) |
IL (2) | IL268093B1 (fr) |
MX (1) | MX2019008529A (fr) |
NZ (1) | NZ755599A (fr) |
SG (2) | SG11201906422VA (fr) |
TW (2) | TWI788323B (fr) |
WO (1) | WO2018136803A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11136372B2 (en) | 2017-01-19 | 2021-10-05 | The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services | ApoC-II mimetic peptides |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4359432A2 (fr) * | 2021-06-23 | 2024-05-01 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Peptides mimétiques d'apoc-ii courts et méthodes d'utilisation |
WO2023215838A1 (fr) * | 2022-05-05 | 2023-11-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Peptides mimétiques d'apolipoprotéine e courte et procédés d'utilisation |
US20240043499A1 (en) * | 2022-08-07 | 2024-02-08 | Protean Bio, Inc. | Peptides for beta-cell survival and insulin production |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
WO1998009602A2 (fr) * | 1996-09-05 | 1998-03-12 | The Uab Research Foundation | Peptides anti-atherosclereux et modele murin transgenique d'atherosclerose |
PL372925A1 (en) | 2001-09-28 | 2005-08-08 | Esperion Therapeutics Inc. | Prevention and treatment of restenosis by local administration of drug |
US7220576B2 (en) * | 2002-01-07 | 2007-05-22 | Lifesensors, Inc. | Methods and compositions for protein expression and purification |
US7691965B2 (en) * | 2002-05-08 | 2010-04-06 | The Regents Of The University Of California | Helical synthetic peptides that stimulate cellular cholesterol efflux |
WO2004066963A2 (fr) * | 2003-01-17 | 2004-08-12 | Merck & Co., Inc. | Derives de n-cyclohexylaminocarbonyl benzenesulfonamide |
US7691860B2 (en) * | 2004-02-19 | 2010-04-06 | Banyu Pharmaceutical Co., Ltd. | Sulfonamide derivatives |
AU2005275009B2 (en) * | 2004-07-16 | 2011-12-08 | Trustees Of Tufts College | Apolipoprotein A1 mimetics and uses thereof |
EP1896496B1 (fr) * | 2005-06-29 | 2012-01-11 | Hadasit Medical Research Services & Development Ltd. | Inhibiteurs de proteine kinase c pour la prevention de la resistance a l'insuline et du diabete de type 2 |
WO2008039843A2 (fr) * | 2006-09-26 | 2008-04-03 | Lipid Sciences, Inc. | Nouveaux peptides promouvant l'ecoulement lipidique |
US20100016173A1 (en) * | 2008-01-30 | 2010-01-21 | Proteogenix, Inc. | Maternal serum biomarkers for detection of pre-eclampsia |
US8936787B2 (en) * | 2008-04-15 | 2015-01-20 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Peptides promoting lipid efflux |
EP2484692A4 (fr) | 2009-09-30 | 2013-03-06 | Snu R&Db Foundation | Peptides mimétiques d'apolipoprotéine a-1, et agent thérapeutique pour traiter l'hyperlipidémie et maladies associées à l'hyperlipidémie comprenant ceux-ci |
EP2917234B1 (fr) | 2012-11-06 | 2020-12-02 | Les Hôpitaux Universitaires de Genève | Peptides mimétiques |
SG11201906422VA (en) | 2017-01-19 | 2019-08-27 | Us Health | Apoc-ii mimetic peptides |
EA201991491A1 (ru) | 2017-03-24 | 2019-12-30 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сервисис | Миметические пептиды apoc-ii |
-
2018
- 2018-01-19 SG SG11201906422VA patent/SG11201906422VA/en unknown
- 2018-01-19 EP EP18742118.5A patent/EP3571216A4/fr active Pending
- 2018-01-19 CA CA3050106A patent/CA3050106A1/fr active Pending
- 2018-01-19 AU AU2018210404A patent/AU2018210404B2/en active Active
- 2018-01-19 TW TW107102123A patent/TWI788323B/zh active
- 2018-01-19 MX MX2019008529A patent/MX2019008529A/es unknown
- 2018-01-19 NZ NZ755599A patent/NZ755599A/en unknown
- 2018-01-19 JP JP2019539809A patent/JP7353973B2/ja active Active
- 2018-01-19 WO PCT/US2018/014532 patent/WO2018136803A1/fr active Application Filing
- 2018-01-19 TW TW109138699A patent/TW202130652A/zh unknown
- 2018-01-19 IL IL268093A patent/IL268093B1/en unknown
- 2018-01-19 SG SG10201911974UA patent/SG10201911974UA/en unknown
- 2018-01-19 US US16/479,183 patent/US11136372B2/en active Active
- 2018-01-19 BR BR112019014707A patent/BR112019014707A2/pt unknown
- 2018-01-19 KR KR1020197024024A patent/KR20190121305A/ko not_active Application Discontinuation
- 2018-01-19 CN CN201880019604.7A patent/CN110831957B/zh active Active
-
2020
- 2020-12-29 IL IL279831A patent/IL279831A/en unknown
-
2021
- 2021-03-09 US US17/195,766 patent/US11827690B2/en active Active
-
2023
- 2023-06-19 JP JP2023100171A patent/JP2023116739A/ja active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11136372B2 (en) | 2017-01-19 | 2021-10-05 | The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services | ApoC-II mimetic peptides |
Also Published As
Publication number | Publication date |
---|---|
WO2018136803A1 (fr) | 2018-07-26 |
NZ755599A (en) | 2022-12-23 |
US11136372B2 (en) | 2021-10-05 |
IL268093B1 (en) | 2024-03-01 |
EP3571216A1 (fr) | 2019-11-27 |
JP7353973B2 (ja) | 2023-10-02 |
KR20190121305A (ko) | 2019-10-25 |
CA3050106A1 (fr) | 2018-07-26 |
TWI788323B (zh) | 2023-01-01 |
US20210324043A1 (en) | 2021-10-21 |
AU2018210404A1 (en) | 2019-08-08 |
JP2023116739A (ja) | 2023-08-22 |
IL268093A (en) | 2019-09-26 |
TW201835097A (zh) | 2018-10-01 |
CN110831957A (zh) | 2020-02-21 |
TW202130652A (zh) | 2021-08-16 |
JP2020511425A (ja) | 2020-04-16 |
MX2019008529A (es) | 2020-02-07 |
CN110831957B (zh) | 2024-02-09 |
WO2018136803A8 (fr) | 2019-08-01 |
US11827690B2 (en) | 2023-11-28 |
AU2018210404B2 (en) | 2022-01-27 |
EP3571216A4 (fr) | 2020-11-04 |
US20200140522A1 (en) | 2020-05-07 |
IL279831A (en) | 2021-03-01 |
SG10201911974UA (en) | 2020-02-27 |
BR112019014707A2 (pt) | 2020-04-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201908391XA (en) | Methods for modulating an immune response | |
SG11201906297QA (en) | Nucleic acids encoding crispr-associated proteins and uses thereof | |
SG11201903454VA (en) | Immunologically discernible cell surface variants for use in cell therapy | |
SG11201809381XA (en) | Polynucleotides encoding interleukin-12 (il12) and uses thereof | |
SG11201806992VA (en) | Antibodies to tigit | |
SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
SG11201909081YA (en) | Anti-ilt4 antibodies and antigen-binding fragments | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201903021WA (en) | Anti-human 4-1 bb antibodies and use thereof | |
SG11201906422VA (en) | Apoc-ii mimetic peptides | |
SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
SG11201809336QA (en) | Anti-pd-l1 antibodies | |
SG11201908420WA (en) | Compositions of plinabulin and use thereof | |
SG11201906192SA (en) | Methods of treating cancer with anti-pd-1 antibodies | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201910096RA (en) | Anti-cd3-binding domains and antibodies comprising them, and methods for their generation and use | |
SG11201811564QA (en) | Methods of treating ovarian cancer | |
SG11202000105QA (en) | Anti-cd166 antibodies and uses thereof | |
SG11201908238SA (en) | Anti-c5 antibodies and uses thereof | |
SG11201901020RA (en) | Anti-siglec-7 antibodies for the treatment of cancer | |
SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
SG11201407579QA (en) | Interleukin-2 fusion proteins and uses thereof | |
SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same | |
SG11201907583TA (en) | Methods for treating complement-mediated diseases and disorders | |
SG11201804673WA (en) | Novel anti-claudin antibodies and methods of use |